Takeda Pharmaceutical Co Ltd (TSE:4502, Financial) is set to release its Q2 2025 earnings on Oct 31, 2024. The consensus estimate for Q2 2025 revenue is 1,094.89 billion, and the earnings are expected to come in at 34.97 per share. The full year 2025's revenue is expected to be $4,407.71 billion and the earnings are expected to be $113.71 per share. More detailed estimate data can be found on the Forecast page
Takeda Pharmaceutical Co Ltd (TSE:4502, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Takeda Pharmaceutical Co Ltd (TSE:4502) for the full year 2025 have increased from $4,371.92 billion to $4,407.71 billion, and for 2026, from $4,415.97 billion to $4,455.86 billion. Earnings estimates have also risen, from $57.28 per share to $113.71 per share for the full year 2025, and from $113.33 per share to $163.70 per share for 2026.
Takeda Pharmaceutical Co Ltd (TSE:4502, Financial) Reported History
In the previous quarter of 2024-06-30, Takeda Pharmaceutical Co Ltd's (TSE:4502) actual revenue was 1,207.99 billion, which beat analysts' revenue expectations of 1,092.77 billion by 10.54%. Takeda Pharmaceutical Co Ltd's (TSE:4502) actual earnings were $60.71 per share, which beat analysts' earnings expectations of $59.98 per share by 1.22%. After releasing the results, Takeda Pharmaceutical Co Ltd (TSE:4502) was up by 1.34% in one day.
Takeda Pharmaceutical Co Ltd (TSE:4502, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 15 analysts, the average target price for Takeda Pharmaceutical Co Ltd (TSE:4502) is $4759.27 with a high estimate of $5900 and a low estimate of $4200. The average target implies an upside of 12.35% from the current price of $4236.
Based on GuruFocus estimates, the estimated GF Value for Takeda Pharmaceutical Co Ltd (TSE:4502, Financial) in one year is $4629.38, suggesting an upside of 9.29% from the current price of $4236.
Based on the consensus recommendation from 18 brokerage firms, Takeda Pharmaceutical Co Ltd's (TSE:4502, Financial) average brokerage recommendation is currently 2.4, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
